Cancer diagnostics specialist Telix Pharmaceuticals has upgraded its full-year revenue forecast following a strong second quarter, sending the market darling’s shares to a fresh record high.

Telix shares, which have doubled in value since the start of the year, hit $20.76 in early trade before dropping back to $19.95, flat on the prior day’s trade, by mid-morning.